Central nervous system (CNS) cancers—including aggressive diseases like glioblastoma (GBM) and leptomeningeal metastases (LM)—remain among the most challenging cancers to treat. Despite decades of research, treatment options remain limited, and very few therapies have earned FDA approval for these indications.
At Plus Therapeutics, we are working to change that.
In a recent Xtalks Clinical Edge interview, Marc Hedrick, M.D., President and CEO of Plus Therapeutics, spoke with Soumya Shashikumar about how our team is advancing targeted radiotherapeutic technologies specifically engineered for precision delivery within the brain and spinal cord.
“We’ve built a platform around highly targeted radiotherapeutics that are delivered directly into the tumor microenvironment,” said Dr. Hedrick. “We believe this approach has the potential to address a significant unmet need in neuro-oncology.”
Our lead investigational therapy, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated across multiple ongoing clinical trials, including:
-
ReSPECT-GBM – for patients with recurrent glioblastoma
-
ReSPECT-LM – for patients with leptomeningeal metastases
-
ReSPECT-PBC – for pediatric brain cancers, recently cleared by the FDA for clinical investigation
Read the full interview on Xtalks to explore our vision for innovation in neuro-oncology:
Click here to access the article
Learn More
To find out more about our clinical trials or targeted radiotherapeutics platform, visit respect-trials.com or plustherapeutics.com.
#NeuroOncology #Glioblastoma #LeptomeningealMetastases #Radiotherapeutics #CNSCancer #TargetedTherapy #ClinicalTrials #PSTV #OncologyInnovation #REYOBIQ #ReSPECTTrials #BrainCancer #CancerResearch #Xtalks #PrecisionMedicine
Recent Comments